Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...

Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...

Kessler scientists' trial set to evaluate non-invasive brain stimulation for upper-extremity disability post-stroke, ...

Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...

The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with ...

NEW YORK (WABC) -- A breakthrough is offering good news for cancer patients who lose their hair during chemotherapy. New York ...